Stockreport

ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF 10min Summary ImmunityBio's Anktiva shows promise in cancer immunotherapy, with initial sales of $900K and ongoing studies in various cancers, including non-small c [Read more]